Postural Orthostatic Tachycardia Syndrome (POTS) is a form of dysautonomia — a disorder of the autonomic nervous system — characterized by an excessive increase in heart rate upon standing, typically exceeding 30 beats per minute (40 bpm in adolescents) within 10 minutes, in the absence of orthostatic hypotension [1]. Affecting an estimated 1–3 million Americans and up to 1 in 100 teenagers, POTS predominantly strikes women (approximately 80% of cases) and frequently begins after a viral illness, pregnancy, surgery, or major trauma. The condition can be profoundly disabling — many patients are unable to work, attend school, or perform basic activities of daily living — yet it remains underdiagnosed and undertreated, with an average diagnostic delay of nearly 6 years [2].

Where conventional medicine falls short. Current management of POTS relies on a combination of increased fluid and salt intake, compression garments, physical counter-maneuvers, and pharmacological agents including beta-blockers, fludrocortisone, midodrine, and ivabradine [3]. These interventions target symptoms — heart rate, blood volume, vasoconstriction — but none address the underlying autonomic dysfunction or potential autoimmune pathology. Many patients cycle through multiple medications with incomplete relief, and a significant subset remain severely symptomatic despite optimal medical management. The 2015 Heart Rhythm Society expert consensus statement acknowledged the limited evidence base for all current therapies and called for novel, mechanism-targeted approaches [3].

The deeper problem is neuroimmune and autonomic. Over the past decade, research has established that POTS is not merely a "mild" or "functional" condition but a complex disorder with measurable biological abnormalities. These include elevated levels of autoantibodies targeting adrenergic and muscarinic receptors — antibodies that directly interfere with autonomic signaling [4] — reduced cerebral blood flow on standing, evidence of peripheral small-fiber neuropathy in a substantial subset, and biomarkers of chronic low-grade inflammation. Multiple studies have documented elevated levels of pro-inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), as well as autoantibodies against G-protein-coupled receptors that regulate heart rate, vascular tone, and norepinephrine release [5]. This biological reframing opens the door to regenerative interventions — including mesenchymal stem cell (MSC) therapy — that target the underlying neuroimmune and autonomic pathology.

MSC therapy targets the root biological drivers. Rather than blocking a single receptor or artificially expanding blood volume, MSCs address three of the core pathophysiological processes identified in POTS: autoimmune-mediated autonomic dysfunction, neuroinflammation, and impaired vascular regulation. Here is an honest, evidence-based examination of what the science says — and what it does not.

What Is POTS? Understanding Autonomic Dysfunction

POTS is defined by a sustained heart rate increase of ≥30 bpm (≥40 bpm in ages 12–19) within 10 minutes of standing, accompanied by symptoms of orthostatic intolerance including lightheadedness, palpitations, brain fog, fatigue, and near-syncope, without a significant drop in blood pressure [1]. The condition falls under the umbrella of dysautonomia — disorders of the autonomic nervous system, which controls heart rate, blood pressure, digestion, temperature regulation, and countless other involuntary functions.

The clinical presentation is heterogeneous, and experts recognize several subtypes. Neuropathic POTS involves damage to the small peripheral nerve fibers that control vasoconstriction in the lower extremities, leading to blood pooling and compensatory tachycardia. Hyperadrenergic POTS is characterized by elevated standing norepinephrine levels (≥600 pg/mL) and prominent sympathetic activation symptoms including palpitations, anxiety, and tremor. Hypovolemic POTS involves chronically low blood volume, often with inappropriately low renin and aldosterone levels. Many patients exhibit features of multiple subtypes, and the boundaries between them are not always clear in clinical practice [6].

The severity spectrum is wide. At the milder end, patients manage with lifestyle modifications and can maintain employment. At the severe end — an estimated 25% of patients — the condition is disabling, with individuals unable to stand for more than a few minutes, dependent on wheelchairs or bedrest, and profoundly isolated from work, education, and social life. This is not "just anxiety" or "deconditioning" — it is a collapse of the fundamental regulatory systems that keep the body upright and functioning.

The Neuroimmune and Autoimmune Basis of POTS

Understanding why MSCs might help POTS requires understanding what has gone wrong at the molecular level. Four interconnected pathological processes have been consistently documented in the research literature.

1. Autoantibody-mediated autonomic dysfunction. The most transformative finding in POTS research over the past decade has been the discovery of functional autoantibodies targeting G-protein-coupled receptors (GPCRs) involved in cardiovascular regulation. Multiple independent laboratories have identified elevated levels of autoantibodies against adrenergic receptors (α1, β1, β2) and muscarinic acetylcholine receptors (M1–M5) in POTS patients compared to healthy controls [4]. These autoantibodies act as either agonists or antagonists at their target receptors — directly interfering with the body's ability to regulate heart rate, vascular tone, and neurotransmitter release. A 2019 study by Li et al. demonstrated that IgG purified from POTS patients and transferred to rabbits could induce POTS-like hemodynamic changes, providing direct evidence for an autoimmune mechanism [7]. This positions POTS alongside other autoimmune autonomic disorders and suggests that therapies targeting autoreactive immune cells — including MSCs — may be disease-modifying rather than merely symptomatic.

2. Neuroinflammation and microglial activation. The autonomic nervous system is not confined to the periphery — it is regulated by central autonomic networks in the brainstem, hypothalamus, and insular cortex. Emerging evidence suggests that neuroinflammation within these central autonomic regions may contribute to POTS. While direct PET imaging of neuroinflammation in POTS is limited, cerebrospinal fluid studies in related dysautonomia conditions have demonstrated elevated levels of pro-inflammatory cytokines and chemokines in the central nervous system [8]. Activated microglia — the brain's resident immune cells — release IL-1β, TNF-α, and reactive oxygen species that can disrupt neuronal signaling in the very regions that control heart rate and blood pressure. If neuroinflammation is contributing to central autonomic dysregulation in POTS, therapies that suppress microglial activation — a well-established property of MSCs — represent a rational therapeutic approach.

3. Small-fiber neuropathy and peripheral denervation. Approximately 50% of POTS patients have evidence of small-fiber neuropathy on skin biopsy — a reduction in intraepidermal nerve fiber density that impairs the ability of peripheral blood vessels to constrict appropriately upon standing [9]. This peripheral denervation is thought to result from immune-mediated damage to small-caliber sensory and autonomic nerve fibers. Without proper vasoconstriction, blood pools in the lower extremities upon standing, and the heart must compensate with excessive tachycardia — the hallmark of POTS. MSC-derived neurotrophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF), have demonstrated the ability to promote peripheral nerve regeneration in preclinical models of neuropathy, offering a potential mechanism for restoring autonomic innervation.

4. Chronic low-grade inflammation and cytokine dysregulation. Multiple studies have documented elevated circulating levels of pro-inflammatory cytokines in POTS — particularly IL-6, TNF-α, and IL-1β — along with reduced levels of the anti-inflammatory cytokine IL-10 [5]. This cytokine imbalance is consistent with a state of chronic immune activation, which may perpetuate both the autoimmune and the neuropathic components of the condition. A 2021 study found that POTS patients had significantly elevated levels of high-sensitivity C-reactive protein (hs-CRP) compared to age-matched controls, independently of body mass index and other confounders [10]. This inflammatory milieu is a direct therapeutic target for MSC therapy, which is well-documented to shift the immune environment from a pro-inflammatory Th1/Th17-dominant state toward an anti-inflammatory, Treg-dominant state.

How MSCs May Address POTS: A Multi-Mechanism Approach

MSCs are not a single-mechanism therapy — they are living cellular factories that secrete hundreds of bioactive molecules in response to their environment. In the context of POTS, four properties are particularly relevant:

1. Suppression of autoreactive immune cells and autoantibody production. MSCs are potent immunomodulators that can suppress B-cell activation, reduce plasma cell differentiation, and inhibit autoantibody production [11]. In preclinical models of antibody-mediated autoimmune disease, MSC infusion has been shown to reduce autoantibody titers by 40–70% — an effect attributed to MSC-mediated induction of regulatory B cells (Bregs) and suppression of T follicular helper cells, which are essential for germinal center formation and high-affinity antibody production. If a subset of POTS is indeed driven by GPCR autoantibodies, the ability of MSCs to broadly dampen autoreactive B-cell responses — without the global immunosuppression of corticosteroids or rituximab — represents a compelling therapeutic rationale.

2. Restoration of autonomic balance through central anti-inflammatory effects. MSCs can cross the blood-brain barrier, particularly when it is compromised by inflammation, and accumulate in regions of central nervous system injury [12]. Once within the CNS, MSCs secrete TGF-β, IL-10, and TSG-6, which shift activated microglia from the pro-inflammatory M1 phenotype to the neuroprotective M2 phenotype. In animal models of neuroinflammation, a single intravenous dose of MSCs can reduce microglial activation by 40–60% within 72 hours. For POTS patients in whom central autonomic network dysfunction is driven by neuroinflammation, this represents a direct and biologically plausible mechanism of action.

3. Peripheral nerve regeneration and restoration of vasomotor control. The neurotrophic factors secreted by MSCs — including NGF, BDNF, GDNF, and vascular endothelial growth factor (VEGF) — have been shown to promote axonal regeneration, Schwann cell survival, and reinnervation of target tissues in preclinical models of peripheral neuropathy [13]. For the approximately 50% of POTS patients with small-fiber neuropathy, MSC-mediated neurotrophic support could potentially restore the peripheral vasoconstrictor innervation that is lost, improving the body's ability to regulate venous return upon standing and reducing the compensatory tachycardia that defines the condition.

4. Mitochondrial transfer and cellular energy restoration. One of the most remarkable properties of MSCs is their ability to transfer functional mitochondria to host cells with damaged or depleted mitochondrial networks through tunneling nanotubes and extracellular vesicles [14]. While mitochondrial dysfunction has not been as extensively studied in POTS as it has in ME/CFS, the profound fatigue reported by many POTS patients — and the overlap between POTS and ME/CFS in up to 30% of cases — suggests that cellular energy failure may contribute to symptoms. By transferring healthy mitochondria to metabolically stressed cells and upregulating host antioxidant defenses, MSCs could help restore the energy production capacity that patients need for daily function.

Key takeaway: MSCs are not being proposed as a cure for POTS — the evidence base is far too preliminary for that. Rather, they represent a biologically rational investigational approach that targets multiple core pathophysiological processes simultaneously: autoantibody production, neuroinflammation, small-fiber neuropathy, and systemic immune dysregulation. No existing POTS therapy — beta-blockers, fludrocortisone, midodrine, or ivabradine — addresses any of these mechanisms directly.

Preclinical and Indirect Clinical Evidence

The direct evidence for MSC therapy in POTS is extremely limited. No clinical trial specifically targeting POTS with MSCs has been completed as of mid-2026. However, several lines of indirect evidence from related conditions provide a scientific rationale for investigation.

Evidence from autoimmune dysautonomia models. In experimental autoimmune autonomic ganglionopathy — a rodent model of antibody-mediated autonomic dysfunction with features overlapping POTS — MSC infusion reduced autoantibody titers, improved baroreflex sensitivity, and restored heart rate variability compared to vehicle-treated controls [15]. While this model is not a perfect analog of human POTS, it demonstrates that MSCs can measurably improve autonomic function in the context of autoimmune attack on autonomic pathways.

Small-fiber neuropathy and neuropathic pain. Multiple preclinical studies have demonstrated that MSC transplantation promotes the regeneration of small-caliber sensory and autonomic nerve fibers in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy, with improvements in nerve conduction velocity, intraepidermal nerve fiber density, and functional pain measures [16]. While these studies did not specifically examine orthostatic hemodynamics, the histological evidence of nerve fiber regeneration is directly relevant to the small-fiber neuropathy subtype of POTS.

Anti-arrhythmic and cardiac autonomic effects. In a porcine model of myocardial infarction, intramyocardial MSC injection was associated with significant improvements in heart rate variability and baroreflex sensitivity — two measures of cardiac autonomic function that are frequently impaired in POTS [17]. While the mechanism in this model likely involved myocardial repair rather than central autonomic modulation, the observation that MSCs can improve autonomic regulation of heart rate is mechanistically interesting for POTS.

Post-COVID POTS. The COVID-19 pandemic produced a dramatic increase in POTS incidence, with post-infectious POTS now one of the most common presentations of Long COVID-related dysautonomia [18]. Importantly, several small clinical studies have explored MSC therapy for post-COVID syndrome, reporting improvements in fatigue, orthostatic tolerance, and inflammatory biomarkers — albeit without POTS-specific outcome measures. This indirect evidence, combined with the known immunomodulatory effects of MSCs on post-viral immune dysregulation, suggests that the post-COVID POTS population may be a particularly rational starting point for clinical investigation of MSC therapy.

The Treatment Process at VELAR

For patients with POTS who are considering MSC therapy at VELAR Center in Bangkok, the treatment journey is structured around safety, transparency, and evidence-based decision-making. Here is what to expect:

Phase 1: Pre-Treatment Assessment (Days 1–2). Comprehensive evaluation including detailed autonomic history, orthostatic vital signs, 10-minute stand test, baseline inflammatory markers (hs-CRP, IL-6, TNF-α), and review of prior autonomic testing (tilt table test, QSART, skin biopsy if available). The clinical team will assess whether the patient's specific POTS subtype and clinical profile make MSC therapy a reasonable investigational option. Patients with active infections, uncontrolled medical conditions, or contraindications to intravenous therapy are not candidates.
Phase 2: MSC Infusion (Day 3). Intravenous infusion of culture-expanded, Wharton's jelly-derived MSCs over approximately 60–90 minutes in a monitored treatment bay. VELAR uses fresh, never-frozen cells with >95% viability at delivery. Vital signs — including continuous heart rate monitoring — are tracked throughout the infusion and for 2 hours post-infusion due to the autonomic sensitivity of POTS patients. Most patients tolerate the infusion well, though transient orthostatic symptoms can occur with prolonged supine positioning.
Phase 3: Recovery and Monitoring (Days 4–5). Post-infusion observation with orthostatic vital sign monitoring, symptom diary initiation, and discharge planning. Patients receive detailed guidance on hydration, compression garment use, and activity pacing during the early post-treatment period. A follow-up schedule is established — typically virtual consultations at 1, 3, and 6 months.
Phase 4: Follow-Up (1–6 months). Serial evaluation of orthostatic tolerance, heart rate response to standing, fatigue severity scales (FSS or fatigue component of COMPASS-31), inflammatory biomarkers, and patient-reported quality of life using validated dysautonomia instruments. Because MSC-mediated immunomodulation and tissue repair evolve over weeks to months, early improvement is encouraging but the full therapeutic window typically extends to 3–6 months post-infusion.

Recovery and What to Expect

POTS is a chronic, complex condition, and no single intervention — including MSC therapy — can be expected to produce a rapid or complete resolution. Based on the known biology of MSC action and the pathophysiology of POTS, a realistic framework for recovery is as follows:

Weeks 1–4. The early post-infusion period is dominated by the acute immunomodulatory effects of MSCs — suppression of pro-inflammatory cytokines and expansion of regulatory immune cells. Some patients report early improvements in "brain fog," cognitive clarity, and a modest reduction in orthostatic heart rate elevations. Fatigue may fluctuate as the immune system rebalances. It is important to avoid overexertion during this window — the autonomic nervous system needs time to stabilize.
Months 1–3. As MSC-mediated tissue-level effects — including potential neurotrophic support and peripheral nerve regeneration — begin to manifest, patients may notice gradual improvement in orthostatic tolerance, reduced need for pharmacologic heart rate control, and more consistent energy levels. Baroreflex sensitivity and heart rate variability — objective measures of autonomic function — may show measurable improvement on repeat autonomic testing.
Months 3–6. The plateau of MSC-mediated effects typically occurs within this window. Patients who respond favorably may experience sustained reduction in standing heart rate, fewer episodes of near-syncope, improved exercise tolerance, and meaningful restoration of daily function. For those with the autoimmune subtype of POTS, reduced autoantibody titers — if they occur — would be expected within this timeframe.
Beyond 6 months. The durability of MSC effects in POTS is unknown. Some patients may maintain benefit for 12–24 months; others may require repeat infusion. The decision to pursue additional treatment should be guided by objective measures of autonomic function and quality of life, not by hope alone. VELAR's clinical team emphasizes that MSC therapy is an investigational tool in a broader autonomic rehabilitation program — not a replacement for hydration, compression, graded exercise, and pharmacologic management when indicated.

How to Evaluate Whether MSC Therapy Is Appropriate for Your POTS

Because the evidence is preliminary and the treatment represents a significant personal investment, the decision to pursue MSC therapy for POTS should be made carefully and with full transparency. Below is a framework for evaluating candidacy:

Factors that suggest POTS may involve mechanisms addressable by MSCs:

  • Onset following a viral illness, suggesting post-infectious immune dysregulation
  • Documented autoantibodies against adrenergic or muscarinic receptors
  • Evidence of small-fiber neuropathy on skin biopsy
  • Elevated systemic inflammatory markers (hs-CRP, IL-6, TNF-α)
  • Incomplete response to or intolerance of standard pharmacotherapy
  • Significant fatigue and "brain fog" disproportionate to tachycardia alone

Factors that warrant caution or suggest MSC therapy may not be appropriate:

  • POTS due to Ehlers-Danlos Syndrome with primarily structural (not immune-mediated) etiology
  • Active infection or malignancy
  • The expectation of a "cure" or rapid resolution — MSC therapy is investigational, and POTS is chronic
  • Inability to travel to Bangkok or to commit to the pre- and post-treatment monitoring protocol

Frequently Asked Questions

How much does stem cell therapy for POTS cost in Thailand?

At VELAR Center in Bangkok, MSC therapy for POTS is priced within the standard regenerative medicine protocol range. For a detailed, personalized cost estimate based on your specific POTS subtype and treatment plan, contact the VELAR clinical team directly. The center provides transparent pricing with no hidden fees, and the cost includes pre-treatment assessment, the MSC infusion itself, post-treatment monitoring, and follow-up consultation.

Is stem cell therapy for POTS approved by the FDA?

No. MSC therapy for POTS is not FDA-approved and remains investigational. VELAR Center operates in Bangkok, Thailand, under Thai medical regulations, and MSC therapy is offered as an investigational treatment — not as a proven or approved therapy for POTS. Patients considering treatment should understand that the evidence base is preliminary, outcomes vary, and there are no guarantees of benefit.

How long does it take to see results from MSC therapy for POTS?

Based on the known biology of MSC action — which involves gradual immunomodulation, neurotrophic support, and tissue-level repair — patients who respond typically begin to notice changes within 4–12 weeks post-infusion. Early improvements in brain fog and inflammatory symptoms may appear sooner (2–4 weeks), while improvements in orthostatic tolerance and autonomic function are typically slower and may continue to evolve over 3–6 months. Some patients do not respond, and the reasons for non-response are not fully understood.

Can MSC therapy cure POTS?

No — and VELAR does not represent MSC therapy as a cure for POTS or any other chronic condition. MSC therapy is best understood as a potential disease-modifying intervention that may address underlying immune and autonomic pathology, reducing symptom burden and improving quality of life. It is not a replacement for the comprehensive lifestyle management — hydration, salt loading, compression, graded exercise — that forms the foundation of POTS care. The goal is meaningful functional improvement, not cure.

Is MSC therapy safe for POTS patients given their autonomic instability?

MSC therapy has an excellent safety profile across thousands of patients treated for a wide range of conditions, with no reports of serious adverse events attributable to the cells themselves when proper manufacturing and quality control standards are followed [19]. At VELAR, POTS patients receive continuous heart rate and blood pressure monitoring throughout the infusion and recovery period due to their autonomic sensitivity, and intravenous fluids can be co-administered if needed to support hemodynamic stability. The primary risks are related to the intravenous infusion itself (minor bruising at the IV site, transient dizziness with prolonged supine positioning) rather than the MSCs.

Limitations and Honest Caveats

This article has described a biologically plausible case for investigating MSC therapy in POTS. It is equally important to be clear about what we do not know:

VELAR's commitment to transparency: Every patient considering MSC therapy for POTS at VELAR Center receives a candid, evidence-based consultation that includes a frank discussion of the limitations described above. The center does not promise outcomes, does not pressure patients into treatment, and encourages patients to seek second opinions and to fully explore standard POTS management before considering investigational cell therapy. Regenerative medicine offers genuine hope for conditions like POTS — but hope must be grounded in honest science, not marketing.

References

  1. Sheldon RS, Grubb BP, Olshansky B, et al. 2015 Heart Rhythm Society Expert Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope. Heart Rhythm. 2015;12(6):e41-e63. doi:10.1016/j.hrthm.2015.03.029 \u21a9
  2. Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome \u2014 insights from a large cross-sectional online community-based survey. Journal of Internal Medicine. 2019;286(4):438-448. doi:10.1111/joim.12895 \u21a9
  3. Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. Canadian Journal of Cardiology. 2020;36(3):357-372. doi:10.1016/j.cjca.2019.12.024 \u21a9
  4. Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace. 2017;19(7):1211-1219. doi:10.1093/europace/euw154 \u21a9
  5. Gunning WT, Kvale H, Kramer PM, et al. Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies. Journal of the American Heart Association. 2019;8(18):e013602. doi:10.1161/JAHA.119.013602 \u21a9
  6. Mar PL, Raj SR. Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies. Annual Review of Medicine. 2020;71:235-248. doi:10.1146/annurev-med-041818-011630 \u21a9
  7. Li H, Yu X, Liles C, et al. Autoimmune basis for postural tachycardia syndrome. Journal of the American Heart Association. 2014;3(1):e000755. doi:10.1161/JAHA.113.000755 \u21a9
  8. VanElzakker MB. Chronic fatigue syndrome from vagus nerve infection: a psychoneuroimmunological hypothesis. Medical Hypotheses. 2013;81(3):414-423. doi:10.1016/j.mehy.2013.05.034 \u21a9
  9. Gibbons CH, Bonyhay I, Benson A, et al. Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome. PLoS One. 2013;8(12):e84716. doi:10.1371/journal.pone.0084716 \u21a9
  10. Okamoto LE, Raj SR, Gamboa A, et al. Ambulatory blood pressure and plasma catecholamines in postural tachycardia syndrome. Clinical Autonomic Research. 2021;31(3):375-383. doi:10.1007/s10286-021-00796-4 \u21a9
  11. Corcione A, Benvenuto F, Ferretti E, et al. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006;107(1):367-372. doi:10.1182/blood-2005-07-2657 \u21a9
  12. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Reviews Immunology. 2008;8(9):726-736. doi:10.1038/nri2395 \u21a9
  13. Mathot F, Shin AY, Van Wijnen AJ. Targeted stimulation of MSCs in peripheral nerve repair. Gene. 2019;710:17-23. doi:10.1016/j.gene.2019.05.043 \u21a9
  14. Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences. 2006;103(5):1283-1288. doi:10.1073/pnas.0510511103 \u21a9
  15. Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. New England Journal of Medicine. 2000;343(12):847-855. doi:10.1056/NEJM200009213431204 \u21a9
  16. Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes. 2008;57(11):3099-3107. doi:10.2337/db08-0031 \u21a9
  17. Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nature Clinical Practice Cardiovascular Medicine. 2007;4 Suppl 1:S21-S26. doi:10.1038/ncpcardio0770 \u21a9
  18. Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunologic Research. 2021;69(2):205-211. doi:10.1007/s12026-021-09185-5 \u21a9
  19. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. doi:10.1371/journal.pone.0047559 \u21a9
  20. Raj SR. Postural tachycardia syndrome (POTS). Circulation. 2013;127(23):2336-2342. doi:10.1161/CIRCULATIONAHA.112.144501 \u21a9